EVENTS
The information contained in each news post on this page was factually accurate on the date it was issued and posted.
Bill Newell, CEO Interviewed by Brad Loncar, Founder, Biotech TV – “Sutro Biopharma’s CEO on ADCs, non-cell protein synthesis, and more”
Bill Newell describes this week’s deal with Ipsen, the folate receptor alpha space, designing therapies with non-cell protein synthesis, and Sutro’s numerous partnerships Speakers: Bill Newell, CEO, Sutro Biopharma Bard Loncar, Founder, Biotech TV
14th Annual World ADC London 2024 – Presentation
Sutro Biopharma to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif., February 6, 2024 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive...
Luvelta Forum – Presentation
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC
Ovarian cancer data supports registration-enabling trial of luvelta for women with platinum-resistant ovarian cancer Potential benefit to 8 out of 10 platinum-resistant ovarian cancer patients, including addressing unmet need in patients with low-medium FolRα...
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024
SOUTH SAN FRANCISCO, Calif., December 14, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that it will host an investor...
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023
– Complete remission seen in 42% of patients with CBF/GLIS AML with ≥5% blasts and 75% of pediatric patients with CBF/GLIS AML with <5% blasts; treatment with luvelta was either alone or in combination – – Luvelta was generally well-tolerated – – Data supports...
65th American Society of Hematology Annual Meeting and Exposition – Poster
Anti-leukemic Activity of Luveltamab Tazevibulin (LT, STRO-002), a Novel Folate Receptor-α (FR-α)-targeting Antibody Drug Conjugate (ADC) in Relapsed/Refractory CBFA2T3::GLIS2 AML Presenter & Primary Author: Dr. Soheil Meshinch
Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit
SOUTH SAN FRANCISCO, Calif., December 4, 2023 – Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive...
